0001728328 false A1 Suite 310 - 815 W. Hastings Street, BC CA 0001728328 2023-11-29 2023-11-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares














Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 29, 2023





(Exact Name of Company as Specified in Charter)




British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)


(Commission File Number)


(IRS Employer

Identification No.)


InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.


  V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)


Company’s telephone number, including area code: (604) 669-7207


Not applicable

(Former Name or Former Address, if Changed Since Last Report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  

Trading Symbol(s)

  Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company  


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  







Item 7.01 Regulation FD Disclosure.


On November 29, 2023, the Company announced the launch of INM-089, a cannabinol (“CBN”) analog, to investigate its effects in the treatment of Age-related Macular Degeneration (“AMD”). INM-089 is the company’s second ocular pharmaceutical program.


The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits:


The following exhibits shall be deemed to be furnished, and not filed:


Exhibit No.   Description


  News release, dated November 29, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 29, 2023By:

/s/ Eric A Adams

  Eric A Adams
    President & CEO





EX-99.1 2 ea189237ex99-1_inmedpharma.htm NEWS RELEASE, DATED NOVEMBER 29, 2023

Exhibit 99.1





Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com



InMed Expands its Pharmaceutical Pipeline with INM-089 Targeting the Treatment of Age-Related Macular Degeneration


INM-089 improves retinal function in in vivo preclinical AMD disease model
Establishes cannabinol (CBN) analog candidate in a new disease target


Vancouver, BC – November 29, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announces the launch of INM-089, a cannabinol (“CBN”) analog, to investigate its effects in the treatment of Age-related Macular Degeneration (“AMD”). INM-089 is the company’s second ocular pharmaceutical program.


Results from a study, conducted under a collaborative research agreement with leading cannabinoid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila (Italy), demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model. Furthermore, in this model, treatment with INM-089 also improved the thickness of the outer nuclear layer (“ONL”) of the retina where the photoreceptors are located. Based on widely accepted ocular research, there is a very strong correlation between the thickness of the ONL, photoreceptor preservation and visual acuity.


Several CBN analog structures were screened in in vitro and in vivo models to select the most appropriate candidate for continued development. InMed selected a specific CBN analog that outperformed its natural cannabinoid counterpart and demonstrated promising effects related to the treatment of AMD.


“We are very pleased that this research has led to the identification of a lead CBN analog candidate to advance to additional in vivo studies as part of the preclinical development program. Early studies show promising neuroprotective effects of INM-089, leading to the preservation of the retinal function at the back of the eye. Neuroprotection in AMD remains an unmet medical need and a new treatment option may help solve this multifactorial disease,” said InMed’s scientific advisor, Dr. Mauro Maccarrone.


“The INM-089 program, in conjunction with the work we are doing in glaucoma (INM-088), expands our ocular pipeline to treat both front of eye and back of eye indications, including AMD,” said Dr. Eric Hsu, SVP of Preclinical R&D at InMed.


From previous ocular research of the parent, naturally occurring cannabinoid CBN, the Company discovered its ability to proactively protect the nerve cells at the back of the eye in the retinal area, potentially preserving retinal function and vision in preclinical models. The results of this discovery led the Company to investigate optimization of the CBN molecule to better target AMD, resulting in the proprietary CBN analog, INM-089


What is AMD?


AMD is the most common cause of vision loss and potential blindness in people over 50 years of age and globally affects about 35% of people 75 years and older. AMD affects the central vision, and the ability to see fine details. In AMD, a part of the retina called the macula is damaged. The two primary types of age-related macular degeneration are atrophic (non-exudative or “dry”) AMD and neovascular (exudative or “wet”) AMD. Dry AMD (approximately 90% of patients) is characterized by geographic atrophy (GA) at the center of the macula in the advanced stage of the disease, and vision can slowly deteriorate over many years due to the loss of photoreceptors as GA progresses. Wet AMD (approximately 10% of patients) is a more severe form of AMD and is characterized by neovascularization (i.e., development of excess vasculature), which can rapidly lead to blindness. In its early stages, AMD may have no signs or symptoms; therefore, most people do not know they have the disease until it is well developed. Currently, there is no cure for AMD; however, there are treatment options that may prevent or slow the progression of the disease. If AMD remains untreated, patients are likely to lose central field vision in the affected eye within 24 months of disease onset.





InMed is developing a pipeline of rare cannabinoids and cannabinoid analogs across a spectrum of therapeutic applications with large unmet medical needs. Our pharmaceutical programs include a recently completed Phase 2 clinical trial studying the safety and efficacy of INM-755 cream for epidermolysis bullosa and preclinical programs in ocular and neurodegenerative diseases.


About Dr. Mauro Maccarrone


Dr. Mauro Maccarrone is an international expert in cannabinoid research working with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy). He is also the 2007 recipient of the International Association for Cannabinoid Medicines’ prestigious Ester Fride Award for Basic Research, the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award, and the 2020 recipient of the Molecules journal prestigious Tu Youyou Award for medicinal chemistry.


About InMed:


InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.


Investor Contact:


Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: cclancy@inmedpharma.com


Cautionary Note Regarding Forward-Looking Information:


This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: targeting the treatment of AMD; the CBN analog potentially preserving retinal function and vision in AMD models; being a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.


Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.


All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.





GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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inm-20231129.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inm-20231129_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20231129_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Nov. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 29, 2023
Entity File Number 001-39685
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea189237-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2023-11-29 2023-11-29 iso4217:USD shares iso4217:USD shares 0001728328 false A1 Suite 310 - 815 W. Hastings Street, BC CA 8-K 2023-11-29 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Vancouver V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea189237-8k_inmedpharma.htm inm-20231129.xsd inm-20231129_lab.xml inm-20231129_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea189237-8k_inmedpharma.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20231129", "dts": { "inline": { "local": [ "ea189237-8k_inmedpharma.htm" ] }, "schema": { "local": [ "inm-20231129.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20231129_lab.xml" ] }, "presentationLink": { "local": [ "inm-20231129_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189237-8k_inmedpharma.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea189237-8k_inmedpharma.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-23-090946-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-090946-xbrl.zip M4$L#!!0 ( $9V?5RYRF9GNGI[NGE_/)1S]=S)4R2,S+477 MOD:$6")"F";ILJ+UOT9&=B^:B_RWN+MS-+"A'M35K*^1@6T;A7A\/!['QLF8 M;O;C0CZ?CT^P3L2I5)B$UA,3"2'^X^*\+0W8D$85S;*I)K%9(U71'E;3Q])9 MU:ZI*H&J^(W')!E?(@VE\KR!OW(F[A0&JMJA5=-.5=NKJEAZ2A2RS\GAU)@U MF*RJ*Z#,T$/VH]PZGU>WP^O/J\9MDVI63S>'U(8Q1$KI:$*,BAD?D:C%I A M^!SKZX]KZ>2B2<&CLS0XP9YB<9=:,XW+;$'='D\H@!9BTJMHLMY*LIDXE'H5 M1U:T3ZDQJ]RC5I=7= L"5.$[4U>9%5J;EP2J2_I(L\UIN,1N8:"!9=K+I.'+ M0*5ZXV)62=&&3#8&%!0)U] *56:M7I-\W3MCH&%00_@OYH&.IQ60#DF5>N:S"9G;'J7@"B4%7-) M,?<2NGD?W=*0:3+\;Q^KM'_7HZK%7D J4P9-5^^$.S M(/MZ3@&;B!2Y4;R1N")_C< HB0H. D@L+O>L#I.U:>@F#]IMF]JLX@2KBBZ# M2DO"ED5(+XM0DF4P"\M].8?Y1(@4VR/%9B0I)$B4Y(0TN8F14VK9 "LLTK9- MQNR#+4N672D95\NEV33U1P4A0;%[FA$BI52*,]XP,91!)CPF D8 MC%E.#9Q7"Q8'3" +X2BH,."3)D3;J!;I8],CQE4X_Y><#O/.[K0>6^:\JHRWMW9M[/O%1E+>@HS"9>>A0*02OTL MZ(V+C>?LXJ'\7&X&J%27EZ4 %&C:51C_XKP+'J5YV5(S<.45C;R21;$" GA? MNFH,ZG:D*8YB(;PN:7/(J#4R6=&-PP6HXQ'SBH(LD-H*^DY07\G"50*O]&H> M\\ECB0\$>AC&9=UB6^X#U-9-7_'+=; H8QA5'],JT_2AHJUCNUXOBWS#"'OE M 2TL*=3U2I\/.A'!FP./XM >7O'?(\.;-X?4["M:@20B@!(-7NR?[%LCE46; MM,\QB7^^==I%;=V M@8@ O>+KF[;^M#];JS(]@!G\\272*!U5S=!**=U6:72 M Q%APK=T59$/B5OH47+*A7DY0H2HI3P! (%O(\6__B-D$H=.]]R_OA[$ UU8 MV7F/B.%JR%_-Q22Y=9C$4P+O/4D<$G38*%65/GPE0;!A)JC!,JCFI^QU)8%] M.>H6OS?JG5J5M#NE3JV-P]:%7F&C^0!]DF3M6N5[J]ZIU]JDU*CN[M1^5$Y+ MC9,:J5Q>7-3;[?IE@VPB[EIPMQUQ;TKMTWKCI'/9."#56"6VNR,FTJF\7\)N MT15X2Y(NVM&GN)(02[^'L[Q:)5O4[O-C[O4M8'V?Z3#'EZT+XM1R8=Y=/G', MD[]HM*I+(\3XF'C?2;,\=9ZQ/CV>WJ=.+WN=F]8#D'M-(N'G$2GFHF>+P'&F MK.U[[1]?>,87WC,N=F<=VV)D6\D+IH16K=$AK5KSLM79;CA=R;0Y,JT1U6QB MZ]!0PH35Z;.0)+I)A/2>O/]!HN@]8@\82C$R%5L!@K6)-* :F$U)L@D4"_ED MZH.$^J,2VP",;!N@KXQF>[4)A7"-(F,0J^A#X#\EU")M@TFX?"0312,52.6A MR;Z7E_WQ\_\1K+2D89MV5086H*I@:1+?HTY$^&>#RK+W^<5,??J>K61(NJI2 MPP)5>N^7 MH\HDZBQD\YTEWYY%L8P8RQJ ?ZJC85>ALY 1?/&%95M>UK$[PC,E<_4N*]8I MGND1U>@941C53QVY$%3EC-FQHC((L(!"&: MS&=RZ4VRS7_?^*0"X].AD[J[0R%QOWINL/K3?'WTHV5+-[DWC=8*II%B/A<5 M4F).S.8W'#OX8ZX.9B$*]=;VWW$JYY$)\\!+R,Q,\@T2,TM6>)8XG[7?5P: M$(%@N?\QC(%!N.V'N\[S_O(Y@P?(:ZA8>(:,(S^,*\2QSOT_^MM ?_56F]2& MAJI/F?E1UAZ,):2AQS[8WMTH!"^(ZC;=Y?G=,*#+-Y7_\A8["YOO-D@U?""R MKEU MM3D1[33I/1-R,G A!QR!F4UM,V9^7Q-N6;5Z]PB MM.7'5KZ(B:20@+]1^#\GI.'O30S^> =8X*USA.6+6'D!$DYOVEV]+$6KN[;JBG6;VY:&LV\"?\LL8L4KRG,UZ-'#)JAP.=@:2.G M%M:#A0-"JRV'7K6K0ZO!^C2U:#GEEYA"%I*B6,7G6;^@@U5#Q]I)'5=KZ+;7 M[AX_?1?+G?M%#55*+] 00.4*U:B\E"Q^GHI6XHP5F4\8IP_/ACP&SR1$?.IY M<4(4ZDA-W;*I>JL8?&TAU$"TO%AFZ8Y\->QO(QH$.$) R%2(4$YM)0_:9/PX M/%RKNSU76%RD;)H08A2#JJ0V81+,LX^,7/8 AC%K?VV.O25$^\KU\SU0,T$] M+PDZ5^0+P=R[H5L'U+@KPG_])R<*V4,+*JO,&.@:(QK/3H+31!%&1AVA*^_N M4)-1L$<9^N^4[2TZ0-IU )R/2E![M[I!H?8#_;80_ MNSOG@$G=+>(M[\C_V3/Y\#V3[=K5_0C2E1Z>9Q\P4"6>H@"[-G7#5'#]KJM/ M2)>I^ABM"@O1V$@N>D9ZB@J!E2@64?"VDLSDW1U;)Y8R'*DVU9@^LM0IL:BM M6+TI;^JVT+O V5FC<(]MF+/-2C("0B;!33^WK >)NC[&=@:B>5R2LLC>D5*T M&-[&*)(3IC$39M^Z!B1&?'UQ=Z<4$V..W/N%][/U7V/E8I.5KCEZ\##B>HBX M8A/JQE1L&&]<(1QI[F*3%3[MG#[]J-DMXZS_].I3(EU=5QG5^.4;_WP4*@4. M4#Z;2AVNFY/\L&J-&EQ&(+"?$S%\9Y\PA)"4F':-=^$@$IX_VA.RI'+<(F(R M$8.*^V0-UOICJF\R50\*HFKEV4?FUCK:EG>PVJ!6U3RL5L;9(64'!7W MNON;V;!3]X\5OZL5B^%67+>L$3/7VO)3XUAI]SNW2EE^;UM>DNC7L.@DBZ;V MI,TLVJW[\1;]=H(^0.2@?69">FJL/$'.O=Q- 4 /_UH0[RT(OF+E>#Q0;!;% M3C&\D#\VZ9IS-!LX?[?8P2T YX2Y-""22BWK=2>)WKHP[C_]\]Y;ZQV38@<< M@=O385=7]ZS//DVR8I?",[PW[SR\^<@5KD\Y(N@]YQ5MQGWG!KFCKLGOL^L: MVBM8U#PZ/+>X/^L%2-TW=0B>Z%RZ62!FO[LG)E('8C)W(*;3^R&NL[T%],7) M,.,E'DZTFPIBE_M+^.27[)WW6MD;EA\+KUR57>03P07R(>C2N<%] &Y/#&J2 M1ZJ.EIY=L>DYP,_=HUB5V[DNZ3ACN'XS#_9])7G^.'VZ?Z5^ TSX(?K_8246 M.S"7+JHSL6"Q'OA8?4-!TM*95*I9-EYV0<&'V'";N( ! !4=O/83)D8$ HDE MTY\K5$_:M@ZAZX*:#\PFY^>5M7N#OS!06K$V6]=DA)",=*=$XNNTT.H!(B;C M9RL7UE 5B\ 8 _Y$PGT"\7%L#W9WI/EM"IGU%,VY2^$L7B729/D*W?SF7)+L M84>SA\X*EE<;&,$P&7@5 _QKQ*^29'WR_EMM8 ME2ZJ'K.8)QN4/O'P!',R11M M]I1>Z+J-\R+ JYN4-#,Y!&P\,T?:PH:J G:H.+\Z= MVF@1*%",K-37[LYS"B.NOEQUA>E%F=T4@P^ _F:/5L3S+;IS)(5G6^XQEE6; M_9Y*DGZ5\!XO0K$# (H2 ^. >HY$7<2.!I[BPJ,S,U, :2SG_KL4$ LT!WY. M78FVF2EM.<"M.XF];OT"A]21)P_C&O.E]F3]XY]F6)K?"L#(97'G\%PH%O:X MM%\QHXD4\8$ZGMCON"7R=H*=P,DMY@6KF96[/@=^!1]F,>N CPNZ)8].?S9] MWF'31V6]>>ZQT44!U^ <81IZ[+47Q[>V,>$)G]A$^BJS)%,QYM>.WV%#(53I M[WGQ-%+$>6R+>T\?,"KF\F,RR23X?%0+/F!_80!EDQFUBE5&+ M'1"9S\@A3WZB+QG&&QRC-XV=@*?TMZ6@99<,Y5F!7IL\RR5U7.NG$K]?4J4V M)?Q2]AXJ14;0A6M)+D2O\Q^!(/@K$$1V'Z3%0ZN#AQ <6C-$)"2$_7=;( _? MK_B8.R,A"S:+RP7B(;GDH<$J("\7]AZ2:]PO^\#5A(^X[1;X\0!' 8<$'TE9 M("43$+?D_9X *JFA8]>%P'J"UXHO=OU[UCH^Z9I)NW[2*'6^MVKMW^0*S2SE M]3\VTEE4_SE23!>8;_8@QX/=G84]+UR-ET>0-4ET9/&%$,5RGWKHHDP+I( " MR!D1B7890-$>9E9(B.=R;@5(\=@(,SY.CH[L@6X"I)#?<2/JUT"C&\[BH;,: M$$-<]34B1IZ' ,_"M><>4K?I)4^WTYG$&ICI._"X0;5D)ECO%0_]73*;8(0+<*/N-6G-1PNZA$2C(=6HN/%'FS?3YKDYM7#_'R M^\\DL^Y/CEAXFJM4YO569V_M8?;]+7^DE9.6&YO_-7#T^U>Y-F MKO2N>?E@#2;9GX9::]:M6NM$2C0?VTUZ>M)\:N3.,O8_X@\IU\R6!M5I55/5 MRUNJY"Z.^]EN]Z1>_\<82O.NKX?U!+ P04 M" !&=GU7\5Y'&?4/ !5;;7/;N!'^KAG]!]2=RSA329%]L7-^25KY)1=/;9]KJ\GG MO1/\+^C?8?^L?W[ZYO"%^Q_?OO!?'Q[]=/*SN.G_?'[Z>F-HLF)?;'4GA>CK M5%EQJ:;BVJ0R:[D'+7&C/3F]&ZL![H0>WN=K<,71Q#D:FF*VOAGV3$JGT1 M/FVP!@_[UV&!6Y47.I))V&YA)AM>RX?]DR4Q7NY^5WUY]5N57-,AAI(>62./ M-=G9Q8_BYOKX]8:ZV]MK;_VKV]WJ?)R,-D3OO/]ZPZT&O)P\N+F=EX^WN0-Q M#T*+.%C?*D#G9>_FI/>/?7%V>3$'YUI7#%M;_V(WI2Z4^'ZKV_YA:T=\Z(AW MTA8Z&UEQ4W36O?A[F46FA,NTQ-%Q2QS+3,92O-\]%EM'+]>]>%\E^^(O6YW= M[LO.[NY>Y]5V]]6ZUSQ-I<:J.AN:O^DL5?%D+/-4=B*3KGOIZ73:6;$DNS!^ M7#LB>\%L^J;.O+]3B,XV_;PO3J2R0N4K4?X(JSZXUEEVH6)Q>C>166R%+JRX M8CU$JF2^%E=ZHA*=*3'5Q;C9@*^WNS_LB3YF5^00HA@KT<^5+%+,*LQ0]$:J M?:T266#B"QF5BP5I(Y:Q,-6#@2D*D_(SB/?5('@_1@ E.SK;\"A\\.MG?][;?;5WV+FUDZ, G-0T/N35?'Q,<2_#:<8>R#LWTEMPG0T.DD-[<8F1- M *%AF45L> W;G[W!SUM]:PY?G&'ODUQ%@!=#K7=Q(F)ME;1*I"96R8+8Y(MS M/_P_L_!:#7=J"SE(M!UC4"2S3 YT9A*Q>7QT^5P@]B1F1,]C'<.GFPW83XH, MDP5;%Z\EMKO;WS<;X2O' MK8M\:O$TZHC-9TG\N30'@8%)_FAY5AOS7&Q2_B5M+#]7 M^=?S%NR2*(F,G(U$DTP6R3Q7L%@>C5LB5KYI>^ML"HRV+%QTRWI%J0WRF7:63<,E\J\-:URK6R9 M0+G#W*2PDBW*>-82M/TRHL!>9H 9F8\*/I2!4.HMN"$ 3,A1KA1;@_(&AB5A MJPX6=3)1@Y> MQAJ?D\3;IO>YU(D4FV>%3&;/6\U&K%*3V2+G+*088[Y@VPG)F-_B\:KX))=# MU/VHU!%ORQS2Y:G)55S[AASOQQ122*._LIH!(D9K@/S@G'BQ^[SR11['JL66:*X&K- MQEA:4&.E%'@F3 >35"'7!?0ZHN:VQDLROD520A_=]F0<:WH5IEH$DON:6%QC MBUB5S>8<=C$)KV&F"FGB5.;)3(37[=A,:Q;.5$E(- 7L#+JN+%Z/\X'__4;K M?+!(9TFS4=&Q#P(#&7T*@]1,=6"AVH*.MHFD ML]BGK37H3?C]5,[$6"4384URJSR;(_IIRHD,7 Q"^0C0"DF:E7 !=JEY=A!I M;SZRB[8&B>*JX/9M0;T/J\Q#*^.%8R)8Z&,PI(N$9+^IR3^!"=D[8D.(P- 1 M$D.D6A2^>:(?D,DJWY$P95[E6Z$302 B&PI486/*4!R+ !MLY8 7^EUGL?M %EPG^#"0(+,W453F^7)*!Y[B_$'XDH42IP@)3^[C",8E MB/=D06!%,E^ 6+PO\YL9Y68H\!*$O=4$$!+^BC @G43&@3G@?B1>X!<2[UZ2 MY[,/3QQUZG/!MB/Z/+G+?WE9\$'8R,SQ=6V+BY4)- -226M5$X\%?Z<&D;=, M&+[(GRC5%,;,:_[>"LSUB ^UID(:"]0.%0"@3&_[K M4U3L3[,QBCV^8.3,C&IGF#Z2)2H& ,"#+3&6"V:$VX!4,0#T8LZ="8K*(%<0 MA#*QTQ4SN"#C3XX5A?A^YSL:Y=]^M>-?I#=,@B*MP\$Q MO,-E+5;/R7&<9"T>2U_4W-,J))-$MC$0J,DKSC('5%G/'4(1 O<)?I%RM4T: MB64*V6/G4,64?%ZG!.=B-E%A:_,R/?5E>EPOTRE02"3($U098C,S65O=E3%7 MF]0H\4$HSF=5=<2[Q88R96ZE=5-NKGIIJHKZ2QW$@!E]:#8V.;F^@[ %T=-> MUVD8$T!S]CGM+4+Q#_X"2G[!O@QXXS'6L@M:"CIRG M^RP.R7E!MO9C0L91U4N:094)FY@II()AL#I5WAXS*;&1,WYQ(^J7B MT(H?>RY@ WX*]OW@F$@L;7YK:?/-!E>&5/L")$3M5'2D/HUGS:]23\T:@1LW M=4=U%CI1'+7O(O('/YA*)V0#4ZAUS)N'BG6^0BWEV8.]*L<'X0GS*D.UBB)^B9AJD MF85.L";K9(J0%39#H#]&?,2>DEFMHL;Z")NN3(-@!P*9M.*.HAM":%].3ZVK M'&@/%*?YBYQ!$,($FY KZT7H0"/#ALN*,>/,KPU9,JN*;R1+JN;_4[LMWI):]L45 M\'6 23Z7"LZ+M42['4XJ3\[>+U[0<"<(6]LKCA!VZ9F_2!&>'264\FQU=B 3 MBA(=0X3[5SXF"X?]AR^PZ@H!!C#YI_: ;X/NY/4=:%V5\A$@O[6)6NJ>4&Z M<>KX7[>\ZYI0,'.>S0WR>2FRJBON"'M%6US(*.N0H0/)Q M0/ --5\BVD)U9L!X/5]Y0-!I-MXY8:DK3VMN=[NOR%7T1/MUZ>G9PD9ZUII( MN^2%D']MNE'U]2^@/P.72]WJ\X1_N[O=G:]6Y0^'9V\N?+5J MN0W]T91YQOPRG[1?BI]-.3-E;4NITP)UBL%_<>]RO+0 MU:!U.?97UUM]@,WYORM&EX^;G^Q\N6KES6.8*ZUK[9PJXA0+=Y463AY"L''D M,]:C\>I82PU]H@HN :B$X"Y]YJJ#-O7#H8%YBL#AKNK>+&U_PJTONFSAVF!Q M&2UMFUSI%H42N1DL]@GR6$6M:$CREMR,BB^Z+ >[%%S!4Y)>.'BLN-#F,A+Z M8B!G;F?T^/%<#:'PK;IY6'$'UL\HEK@!R# M3\HLI,Y/*TF_NB[[[S>[*]:_W1?1!$C8O7=V3]P!LWS'LN2$QLP MY252/0!JA'R"J!)<1ZE%^]P8SA#/YI3WR [_Q&E$GXX4,C7E8W%N)=&A/?=H M?'-RZ+>>N*U3A*WV'@ZNR 56#Z?N5\'7;VP8O$DW=90_<6D]]-[]59Z'+@_W M+97,6!KJW;I:=9!0'S!";"OH;#B14Q>D'IJ6TH=!N(L"]AHGUI7%?1L=@%YUVV3>Y";KDC(S M[X+N,SEEL^&N4]C0S:_YXN)%BD7/; E_%XEOND"GT+J&B9R/\&%JW66=$Q,D MW-7%#%Y#9"XQU G_35/5>KFIF-S5#*=WT5AF(Y=@:;^#C$L) M8+DS,K??"I:3Y(OF=48EG7^&6D$;=&*I_8$33)=3LY1A0J=?\XRFHG/7='$5 M-9M-ZM0R/,T@H:L#M K03%MF(L7<.=*QJT__,W@=H(.^4;BDGJIJ[8^X4NT$YKI,5#NB4R/^LGQ(M"+EN73V%/:HU7M!?A[L_%Z>_*O\W4$L# M!!0 ( $9V?5=5ET%S*0, .D+ 0 :6YM+3(P,C,Q,3(Y+GAS9+56 MVW+:,!!][TS_0?5KQS:&H2T$DFE)TC(EEPFY]:DC;!D49,F59"[]^DJV92X& M K3UD[Q[SME=:5=VZVP6$3!!7&!&VY;G5"R J,\"3(=MZZ%O?^YWNET+G)V^ M?0/4TWIGV^ 2(Q(TP3GS[2X-V0FXAA%J@J^((@XEXR?@$9)$6]@E)HB##HMB M@B12CBQ2$]2=:@4"V]Y#]Q'1@/&'NVZA.Y(R%DW7G4ZG#F43.&5\+!R?1?L) M]B64B2C4*K-*_NQ'O\+"+\COOX_KXN/L#C^/$OHIN1Y\\\43A#=S>"M_QXWZ M_ ?YDGPET_ ^@H/Y^*6&)Y51![X,W7ES>M M.8P/W6JEXKG/5[U^BK,R8'-&,!UO@GN-1L--O09:0LX&G!CIFJO= RA0H:R\ M> <>4R$A]5?P@2P(R^"ZFSE7H'@C]$,&Q08:H#6<0+XS9!-7.12^6C/ 1-A# M".,"'$(Q2$5SQPI8<%D&*N,ZR);S&(F-T,RU0NA>7Q503",4Q"/((ZB[,L5Y M7K6A9HN@"%%YR7ATCD*8$)7*KP02'&(46$!"/D12MYF(H8]>%S3M"BEEJJO5 M:.46;8MCK-JV,"B3/N8F9P3=J_R!7JBQVAI%^]T.4[>#!7#0MK+EDIY1#%"( M*4ZCYY/D 5O/3:*+5AI53UER/DY9#?7A\1/ MR%'417Z[F+G=[&5ID\U W:$0I(/8U"W3M@365Z&5VT8DL1B!PY+PO".2&++C;XIOM@&UXNTA?8-NN7+ ML#/H1HZ+B!3&]G1>8Z;OXJ@F M\%E")9\?T@C+%/-RW&DL_@#V.PB#SPY!_Q0<&_:(+B@'W]0"+3=34\L_4$L# M!!0 ( $9V?5?)U'6G_0H ("& 4 :6YM+3(P,C,Q,3(Y7VQA8BYX M;6S-G5UOX[@5AN\+]#]PW9L6&,>)@Q9(=F87&4^R,#:;9&//;-M%L: EQA%" MDP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__KC;4/1"1)IP]FETT_/)Y/7U]8CQ%_S*Q5-Z%/'-L H7&ZX_%.$?Z0)>SI7?ZUP2I \7BP]WZ7)IY':;[G;U],C+M:3Z?'QR>2? MOUPOHD>RP>.$J>,6D9&.4K78XD[.SLXF>:F6MI2[E:!Z'Z<3;:>J698F'?J: MDS0Y3W-[USS"6=[MO;M!H$+];ZQE8[5I?#(=GYX<[=)XI ]^?@0%I^2>/*"\ MF>?9_EFBE":*A%&Y[5&0![L9*L1$Q4\86>.,Q&I'9VI')_]0._I+N?D:KP@= M(:64?(#M.FO4509-7)N](R+A\25[GVLSVI-]^=T1V?_0@'J\\R8L>8;IN\S7 M(YW;OB'O.^*'./='6H[SY'U'NA;Y?[&=M2V_^?#:CRM5&Z_EIX9%LLOD!$9B M;5)5T3$"YWO()X:R[JIV'C7JI6HTYZ+==C4SYG6F)#I:\Y=)3!)9]_14?1BK M#WFSY7_^F'&Y$KA8I9G 4:9KRIOQ:60IGYB6E/)":%]81#V-*Q63B,NIZ3D; MT^(P%N$/@F^LNRU;S2V%?]!5%5\<%KD+P&A#)DC*MR(B;^J5NEOH*)6.-E0J MU)**L/'7Q>B'7(-^UZK_?)P<:G'0T7()M-T0EBUEC986-(M==;/-E.[E>ED0 MG6PQ9/:QEB"E<=S!%W+'L=KY%<5KBWVCW%476VWI/FX4!M')-D=F+U<:I$2^ MNOD+22.1/*OE?%<[&C+GG6XQV>K[FB8L!-K&8!)J6D\#^SU9)VIJ41;4^2U1 M&SN&,4#O>NCOM&W.!59Q$- ,<0C.%O4@5$5YXNB"L2VF]^29BRY\FC+7U-A, MFK#4-4$Q8C$&HE%H42'V1,2O6WG&3@3=]T+14KKF K!JHF'(@J+#[@T$I)+[ M960I,$L3-8#U0M*6.C_= ,RV3CT,75"< .;@4Y)*[Y>4Q2.A5-T/P*Q_0+&) M7=,"&S9Y:2N#(@:T!S*31Z R)!QL+E_4ZEPNDP8VMJ;W"4_+=A<_E3A8A$R' M RG*PY"*\T12[39$#T,MI6MZ *LF-X8L*&+LWD!6"CG*]?XAN63Q($0JG1] M#)MV/$I1@' TG?6A(=4^P;A*T@C3PLN5W)9V-,^B=0T(:->$I"4,"A3('0A+ M$:"9R4.\ O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U ,ML*T7 -SSBPU-E- MV1ZSU?U90!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y61%@:UY:X8@,RIYDP MRX-@ 3!E,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I:&H"(L%J#*#AH,V? M*?5"Q$R.3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F 12E&N1I)N1J:(M=(L&9+3)AJD*" [ &D!'J4:+^DN)Y\!Y* M0+U;6'IL-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P ]S,>PRN4GBBW M4 UJ0A.MSI" !OB$\"L$?JA>"8%3UX!4C5X(>XBCN6!2LM_KA-&3L#V M6[5NZ>JPVV3*(@R()-@=P$^I_* _(!6#;EDHT$S?T-2I?VBF0Z&9!@W-]#W0 M+%]Y(-""N6_-7V<#:H](),VZH5 MF(,L/%Q:WOI@40%J/:-"?&*2+ZQNQ9W@+PF+X"4S)/<"#&#:2HVA#0\=N\$^ M?JH%L8[S.M84B_+>+XF6^1EEFB;M0TRA"0^2IK'>P:50^T3BCJ<9IO].GCM/ MQ.UB+WA8#5LA:2C#0\5FKP^8(@;)(!\GUB6NZH:&]54RH]S=*\ 66X=7@&N% M04!@<]1^!;BX>E*(7'>S8E00#(P(S6)GG6PQ5?5QK2R,+FX;:O5P_KV6&A]? M9)7=A=X]<@8_(-"6N.IIR)SN;;,\B!X'3)F]GLM0KO-T-5YEF$CMPW>MS-G, M;MJI)G)=$$3OFFY:T[0N=]R;OXDDDWN>\[G)DDE%K4%#O&8L%I$B59PM:_R)-/D6!;JVPB5T# !C4-;440*("V3 X. M0J25CB&X$T1!2&1'Y"\!JL1"XO;AP3K;=XE=0=%O6,,!*X. I->>"8L,&$>U M"%2$H#S&+S;S--T2\29X+"&>$ +- R"U]"'B!)GLA:H(],G6@D1;.3_N3Z:K M99)1V\EE6^)L3@+,53.241X$&X IDX6\#/$'=#+]Z^IO2$O+W^AK3T/^Y2YZE*8(\$*"7>9ZZ+>9-(?_NB8(!#J,M4Y*2BG2 M6A\O)!RFK'7_(F#M;1&P[ED$K$-K=%BA Y+MVN:++&0'+" M3K5K*#HLFWQ8I$&A OL#QXPJ!!UB7&>TS%.D;IUN689&_2RYL M(Q.@P/9"$96G+T-24H>R3HLOP9NGHF^*(> M7[\T$D7JA8AB5DBD ZQ#$UMY)A M43^/RTW,,[(!WW;H#W%%T%#SFJ,^?1 T#31I,I6'-4^N\T"D(GUF,ZHGMX>7 M> V1XY6QQ:"Q,*XI@F $M 4MB^N_%> G=]YV19/HBG(,7V5I:!QGS&O;,Y+E M'00!$=!V!:7(RX4H5WKI_\^8/8GM&- XR9#1T1 Z VP"=UPR"-1'OH!%<&H%NWI_"P]9 $D\>?]/7D@ M0KUWL"2[[+/%;W4*G>BFJ5X!6ZAFQL@KT MNZH$Y;78?K^\ONE:?I*;]2;YUPJG1&[Y+U!+ P04 " !&=GU7NV;'A%<' M #:5P % &EN;2TR,#(S,3$R.5]P&ULS9Q=<^(V%(;O.]/_X-)K M()!NVV23[B1LV&$VNTE#=K?MS8ZP!6@B2XPD!_CWE6S,\F'))S<^R45"S*N/ M]SFV[&-+OGBW2GGT3)5F4ERV>IV35D1%+!,F9I>M+^/VU7@P&K4B;8A(")>" M7K:$;+W[Z^>?(OMS\4N['0T9YN?&+/1YM[M< M+CM"/I.E5$^Z$\L45N'8$)/I;6TGJY/-3U'\@C/Q=.Y^38BFD>4E]/E*L\N6 M:W?3[/*T(]6LVS\YZ77_^70[CN8MLI2KI:J:G>N\>[VTSD5?A_FN7LK;;U.[UVZ>] MSDHGK1)^3E!)3A_H-')_;?2VK3*1TF0Q)RHE+F9=]WUW(.T^:3N;EYPK.KUL M69VMOW_:Z_7/7.V_[FG,>F%W3$KHS=H6A2 M5N2:?T'?##-.O]EC>E';[5Y9:INS'POEIB]E;[B,]SK 71CD@=ERE\YA:QIW M9O*YFU#6=03)(JH0JR[JLBZAX+UK'>^=&T5T092MJQW/&MX&>*IGZZ&Q( M2$]'=T'9)IJA>67;3UP?AIS,JG$>2( \>QA *]U@$7U/=:S8PG&I ;NG!/+M MH_*M\-8PYO+8>: SYOKKNN+.N=1M#(\+GB) \*>8(T70+5($KH3("'^@"ZEJ MP.\K@;Q_P^1=Y0T)\]\9488JOH:0/A(#8;_!A.UQB,3[41&AF>,# 7ZL!A+_ M'?7"P^,1"?EX3CEW>1P1H+V\2@_$_@8P.=]+ M;0C_CRWJKB2K]5#FB(EKR&C3-QB+N+N;%KZI1 <2*%^47+723M-(7805)?[= M=U\!!8J2@%:9:9CGK73//N92!._''JN@7%$R29^II@=>-Y=8>P_]G:_!,]A0 MAM5#&PUC_*:8L3T8R#3-Q.8>C>>IF$<*Q8N2_@7M-8QZ+#F+F6%B]LE>(2I& M>#7G*AT4,DJRYS?6,.%[15VDJ;WLSN=QN<4&ZFXZ]8V\(3V4.$JN5V\4E_Q( MZXRJE_*O* 6- DK:!S7=]#A#X\P.>^M>?_+H5LQX1IDC%90U2LKG,]4PV\_R M41&W8&^\3B>2^Y>'5 JAA%$2O("UAB'O]:,:[X$$"A8ELZNT@S0FW*SB.1$S MZI^]4*V$ D;)]$+FT,;>&6CLG;UP[$7)^'RFD-@6<\/M$74WX6Q&_"O)@@7 MZVPPB0>L-KU^+U_RXY9RJS3OQ]!^J,;ND4*!XRR1#-EK&G66,$.3HDM#)HB( M;4JU7=?FR<[K2T$#@+.&$F@:Y?;^-\KY1R&78DR)EH(FQ:5^Z Z_MP@T"HC/ M$&OLHH3@J^29I:3RB:#*Z7MBR*:'(?Z^$E#^B \4PV;1YL^K@3WQS&3XF?F!$$H; M<2ILI344R..4<'Z=:2:H#HXM!T(H9,0YKY764"#?I%3-[*#V0PI H2/.; U:Q8&_^K&.O%C_%B1?H0:_G0 1N]TEM\8W[Y5[$:K?\#U!+ 0(4 Q0 ( $9V?5#DY+3%?:6YM961P:&%R;6$N:'1M4$L! A0#% @ M1G9]5U6707,I P Z0L ! ( !8"0 &EN;2TR,#(S,3$R M.2YX